Lymphocytic leukemia

Global T-Cell Leukemia Epidemiology and Patient Flow Analysis & Forecasts Report 2020-2035 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 12, 2021
Health, Oncology, Lymphocytic leukemia, Medical specialties, Branches of biology, Clinical medicine, Leukemia, T cell, T-cell leukemia, Large granular lymphocytic leukemia, Lymphoid leukemia

b'The "Global T-Cell Leukemia Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal T-Cell Leukemia Epidemiology and Patient Flow Analysis - 2021, provides T-Cell Leukemia epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global T-Cell Leukemia Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal T-Cell Leukemia Epidemiology and Patient Flow Analysis - 2021, provides T-Cell Leukemia epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize T-Cell Leukemia patients, history of the disease at the population level (T-Cell Leukemia prevalence, T-Cell Leukemia incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: T-Cell Leukemia patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for T-Cell Leukemia market sizing, assessing market potential, and developing drug forecast models\nIdentify T-Cell Leukemia patients segments through age groups, gender, and disease sub-types\nEvaluate T-Cell Leukemia market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210512005460/en/\n'

Hairy Cell Leukemia Epidemiology Forecast 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 7, 2021
Pharmaceutical, Health, Oncology, Lymphocytic leukemia, Leukemia, Hairy cell leukemia, Epidemiology, Medical specialties, Clinical medicine

The "Hairy Cell Leukemia - Epidemiology Forecast 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hairy Cell Leukemia - Epidemiology Forecast 2030" report has been added to ResearchAndMarkets.com's offering.
  • This 'Hairy Cell Leukemia - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical, and forecasted Hairy Cell Leukemia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • This section encompassing Hairy Cell Leukemia epidemiology provides insights about historical and current patient pool and forecasted trends for every seven major countries.
  • What are the key findings of the Hairy Cell Leukemia epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2017-2030)?

Worldwide Hairy Cell Leukemia Drugs Industry to 2025 - Cumulative Impact of COVID-19

Retrieved on: 
Thursday, January 14, 2021
Clinical medicine, Medicine, Cancer, Lymphocytic leukemia, Leukemia, Hairy cell leukemia, Chemotherapy

This research report categorizes the Hairy Cell Leukemia Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:

Key Points: 
  • This research report categorizes the Hairy Cell Leukemia Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
    Based on Product Type, the Hairy Cell Leukemia Drugs Market is examined across Chemotherapy Drug and Immunotherapy Drug.
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Hairy Cell Leukemia Drugs Market during the forecast period?
  • What are the technology trends and regulatory frameworks in the Global Hairy Cell Leukemia Drugs Market?
  • What are the modes and strategic moves considered suitable for entering the Global Hairy Cell Leukemia Drugs Market?

Global Hairy Cell Leukemia Drugs Market (2020 to 2025) - by Product Type and Distribution Channel - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 14, 2021
Health, General Health, Lymphocytic leukemia, Leukemia, Hairy cell leukemia, Medical specialties, Clinical medicine

What is the market size and forecast of the Global Hairy Cell Leukemia Drugs Market?

Key Points: 
  • What is the market size and forecast of the Global Hairy Cell Leukemia Drugs Market?
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Hairy Cell Leukemia Drugs Market during the forecast period?
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Hairy Cell Leukemia Drugs Market?
  • What are the modes and strategic moves considered suitable for entering the Global Hairy Cell Leukemia Drugs Market?

Innate Pharma Launches HopeConnectLearn: A New Online Resource for Hairy Cell Leukemia Patients

Retrieved on: 
Thursday, November 5, 2020
Lymphocytic leukemia, Hairy cell leukemia, Leukemia, Dat, Organ systems, Medical specialties, Clinical medicine

ROCKVILLE, Md., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH ISIN: FR0010331421; Nasdaq: IPHA) ("Innate" or the "Company") today announced the launch of HopeConnectLearn, a new online resource for the hairy cell leukemia community.

Key Points: 
  • ROCKVILLE, Md., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH ISIN: FR0010331421; Nasdaq: IPHA) ("Innate" or the "Company") today announced the launch of HopeConnectLearn, a new online resource for the hairy cell leukemia community.
  • HopeConnectLearn provides education and connection for patients and their caregivers across the spectrum of disease, from a new diagnosis to relapse or refractory experiences.
  • About 40 percent of patients will relapse in 5-10 years following first treatment.iii_iv
    "When facing a rare disease like hairy cell leukemia, patients derive hope from hearing directly from other patients and learning about their experiences," said Anna Lambertson, Executive Director of the Hairy Cell Leukemia Foundation.
  • Based in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

The Hairy Cell Leukemia Foundation and The Leukemia & Lymphoma Society Join Forces to Find New Therapies for Patients with this Rare Blood Cancer

Retrieved on: 
Monday, November 2, 2020
Lymphocytic leukemia, Hairy cell leukemia, Cancer, Leukemia, Medical specialties, Clinical medicine, Chronic lymphocytic leukemia, Chronic leukemia

First described in the late 1950's, HCL is characterized by overgrowth of abnormal white blood cells that compromises the production of normal blood cells.

Key Points: 
  • First described in the late 1950's, HCL is characterized by overgrowth of abnormal white blood cells that compromises the production of normal blood cells.
  • It is named for the uniqueshort, thin hair-like projections on the surface of these blood cancer cells.
  • Approximately 10 to 15% of HCL patients have the variant type of HCL, a more aggressive form of the disease.
  • "Hairy cell leukemia is a rare form of blood cancer and so it is critical for us to join forces to make more progress happen in treating this disease," said Marc Stadtmauer, president of the Hairy Cell Leukemia Foundation.

Potent Preclinical Antitumor Activity Demonstrated by Janpix’s Selective STAT3 & STAT5 Monovalent Degraders to be presented at the Virtual Annual Meetings of the European Hematology Association and American Association for Cancer Research (Part II)

Retrieved on: 
Monday, June 15, 2020
Lymphocytic leukemia, Acute lymphocytic leukemia, Leukemia, RTT, Tumors of the hematopoietic and lymphoid tissues, Prolymphocytic leukemia, T-cell prolymphocytic leukemia, Myeloid leukemia, Medical specialties, Clinical medicine

This is the first time that a monovalent small molecule has been shown to degrade both, STAT3 and STAT5.

Key Points: 
  • This is the first time that a monovalent small molecule has been shown to degrade both, STAT3 and STAT5.
  • These compounds show activity across multiple hematologic malignancies including acute myelogenous leukemia (AML) and T-cell prolymphocytic leukemia (T-PLL).
  • Data will be shared in poster presentations during the 2020 European Hematology Association Virtual Meeting (Abstract #EP436) starting on Monday, June 15th, and the 2020 American Association for Cancer Research Virtual Annual Meeting II (Abstract #10643) starting on Monday, June 22th.
  • Highlights of the presentations include:
    Rapid, potent, and highly selective degradation of STAT3 & STAT5 in leukemic cells upon treatment with JPX-1188.

2020 B-Cell Chronic Lymphocytic Leukemia Pipeline Assessment: Therapeutics, Drugs, Companies, Developments

Retrieved on: 
Tuesday, March 24, 2020
RTT, Cancer, Lymphoid leukemia, Leukemia, Chronic lymphocytic leukemia, Lymphocytic leukemia, Breakthrough therapy, Prolymphocytic leukemia, Chronic leukemia

DUBLIN, March 24, 2020 /PRNewswire/ -- The "B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 24, 2020 /PRNewswire/ -- The "B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2020" report has been added to ResearchAndMarkets.com's offering.
  • This pipeline guideB-Cell Chronic Lymphocytic Leukemia - Pipeline Review H1 2020, provides comprehensive information on the therapeutics under development for B-Cell Chronic Lymphocytic Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for B-Cell Chronic Lymphocytic Leukemia and features dormant and discontinued projects.
  • The pipeline guide reviews pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

Chronic Lymphocytic Leukemia Market, Forecast to 2025 - Roche, AstraZeneca, Verastem, Novartis, and AbbVie are Dominating

Retrieved on: 
Thursday, February 27, 2020
Leukemia, RTT, Lymphoid leukemia, Lymphocytic leukemia, Non-coding RNA

DUBLIN, Feb. 27, 2020 /PRNewswire/ -- The "Chronic Lymphocytic Leukemia Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 27, 2020 /PRNewswire/ -- The "Chronic Lymphocytic Leukemia Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.
  • The Global Chronic Lymphocytic Leukemia Market is anticipated to grow with a CAGR of nearly 2.1% during the forecast period.
  • North America is expected to dominate the overall chronic lymphocytic leukemia market throughout the forecast period.
  • The Chronic lymphocytic leukemia market is moderately competitive and consists of several major players.

Hairy Cell Leukemia Industry Insights by Therapy (2020-2025): Chemotherapy Expected to Register Significant Growth

Retrieved on: 
Monday, February 17, 2020
Cancer, Medicine, Clinical medicine, RTT, Hairy cell leukemia, Lymphocytic leukemia, Leukemia, Cladribine, Purine analogue, Pentostatin, Chemotherapy

In recent years, there are advanced diagnostic tests to detect the hairy cell leukemia.

Key Points: 
  • In recent years, there are advanced diagnostic tests to detect the hairy cell leukemia.
  • Chemotherapy drugs, specifically purine analogs such as cladribine and pentostatin, are considered as an initial treatment option for most individuals with hairy cell leukemia.
  • Additionally, the increase in funding for companies involved in the research related to hairy cell leukemia is expected to boost the studied market.
  • The hairy cell leukemia market is competitive and many of the global players are into the market.